TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06620757

Intervention type: DRUG
Intervention: Single antiplatelet therapy (SAPT)
Description: Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding
Study: NCT05785741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered I.V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered I.V.
Study: NCT06623370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
Study: NCT06623656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenously
Study: NCT06243991

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Disease Index Qestionnaire
Description: The Ocular surface disease index (OSDI) questionnaire consists of a total of 12 questions categorized into three subscales as follows: ocular symptoms, vision-related function, and environmental triggers. Each patient is asked to rate the symptoms on a 5-point scale ranging from never (0 score) to always (4 score) for every question in the questionnaire. The fourth and fifth questions in the first section, concerning blurred vision and reduced vision symptoms, were excluded from the questionnaire as these symptoms may already be present in patients with keratoconus disease. The total OSDI score was calculated according to the formula: OSDI = \[(sum of scores for all questions answered) × 100\] / \[(total number of questions answered) × 4\].

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Disease Index Qestionnaire
Description: The Ocular surface disease index (OSDI) questionnaire consists of a total of 12 questions categorized into three subscales as follows: ocular symptoms, vision-related function, and environmental triggers. Each patient is asked to rate the symptoms on a 5-point scale ranging from never (0 score) to always (4 score) for every question in the questionnaire. The fourth and fifth questions in the first section, concerning blurred vision and reduced vision symptoms, were excluded from the questionnaire as these symptoms may already be present in patients with keratoconus disease. The total OSDI score was calculated according to the formula: OSDI = \[(sum of scores for all questions answered) × 100\] / \[(total number of questions answered) × 4\].

Intervention type: DEVICE
Intervention: Corneal tomography
Description: Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.

Intervention type: DEVICE
Intervention: Corneal tomography
Description: Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.

Intervention type: DEVICE
Intervention: Corneal tomography
Description: Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.
Study: NCT06623656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum based chemotherapy
Description: Intravenously

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: 8 Gy times 3 treatment days (Days 1-3)
Study: NCT06623461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Immune Checkpoint Blockade
Description: Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment
Study: NCT05255068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMAL
Description: A person-centered mealtime care intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMAL
Description: A person-centered mealtime care intervention
Study: NCT06680596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab derxutecan
Description: T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment).
Study: NCT06630299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL/LEN
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL/LEN
Description: Tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISL/LEN
Description: Tablet administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral Combinations
Description: 2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.
Study: NCT06695637

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: active cTBS
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique which employs magnetic fields to stimulate neural activity in the brain. cTBS is a specific TMS protocol, wherein bursts of high-frequency magnetic pulses are repeatedly applied in a rhythmic pattern, mimicking the theta rhythm of neural oscillations. Studies suggest that cTBS has the potential to modulate cortical excitability and synaptic plasticity, leading to alterations in targeted brain function.~Baseline measures will be collected to develop individualized targets for stimulation and also understand how brain structure and activity may change in response to cTBS.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: sham cTBS
Description: The intervention group receives cTBS and the control group receives sham stimulation using the sham option in the coil that makes the same noise and feeling without delivering significant amount of magnetic energy into the brain. Both groups are exposed to drug and neutral pictures before and after receiving stimulation. People in the active group will receive cTBS with corrected individualized stimulation intensity to have 1 V/m in targeted brain regions while in the sham group people will only receive sham condition with a similar look, sound, and feel of active stimulation.
Study: NCT06634173

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAPI PET/CT
Description: This study applies the radiopharmaceutical 18Fluor-FAPI-74 (FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated Cancer associated fibroblasts as a marker of Tumor Micro-Environment and indirectly as a marker for malignancies.
Study: NCT06633653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
Study: NCT05342779

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stripping of great saphenous vein
Description: I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stripping of great saphenous vein
Description: I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure.
Study: NCT05708989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Block
Description: Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Pudendal Block
Description: Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine
Description: Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.
Description: Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
Study: NCT06516003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Goggles
Description: Immersive Virtual Reality goggles are a head mounted device placed over a patient's head and eyes that allows them to play in a virtual reality game.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Distraction techniques like tablet, phone, television, parent, child life specialist
Study: NCT05422612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A Fluoxetine Hydrochloride (HCl)
Description: Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention A Placebo
Description: A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention B Vilazodone Hydrochloride (HCl)
Description: Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention B Placebo
Description: A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention C Daridorexant
Description: Daridorexant will be administered 50 mg once daily.
Study: NCT05688215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo core biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Given IV
Study: NCT06623461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Immune Checkpoint Blockade
Description: Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LND101
Description: Approximately 40 capsules (total of 80-100g of processed fecal material) taken by mouth 7 days prior to the ICG agent(s) administered following bowel preparation.
Study: NCT05386589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four 200 mg capsules administered orally as a single dose
Study: NCT05894629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)
Description: 12-week program consisting of PNE and TE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Usual treatment
Description: 12-week program consisting of home exercises, performed 3 days/week.
Study: NCT05894928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-783
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-783
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-783
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Administered orally.
Study: NCT06001125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 20 mg PO weekly
Study: NCT06479629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piracetam
Description: 800mg oral tablet of Piracetam three times every day for 3 months
Study: NCT05871294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation
Description: The sound used for treatment is selected based on the patient's tinnitus frequency and loudness. Patients receive 90 minutes of acoustic stimulation therapy every day (at least 5 days per week). The entire treatment period is 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: The course of repeated transcranial magnetic stimulation therapy is 4 weeks, with 5, 5, 4, and 3 treatments per week, each lasting 90 minutes (including rest time)
Study: NCT04182360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.
Study: NCT04906213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin10Mg Tab
Description: Empagliflozin10 Mg daily or placebo daily for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin10Mg Tab
Description: Empagliflozin10 Mg daily or placebo daily for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 10Mg Placebo Tab
Study: NCT06479629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch tablet
Study: NCT05517434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation
Description: Participants will undergo a bone marrow aspiration. About 10 mL of BMA will be collected from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest using the Cervos Marrow Cellution™ kit. The BMA does not require processing using a centrifuge after collection. 9 mL (or less) of BMA is injected into the osteoarthritic knee joint after collection (Arm A, Study 1).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo Comparator for BMA)
Description: Participants will undergo a bone marrow aspiration to collect about 10 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent (9 mL) is injected into the osteoarthritic knee joint (Arm C, Study 1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations
Description: Participants will undergo a lipoaspiration. 40 mL of lipoaspirate (LA) will be collected from subcutaneous adipose tissue. LA will be processed using the Cervos LIPO-PRO™ kit and a centrifuge. Participants will also undergo a blood draw. About 30 mL of whole blood will be collected from the antecubital fossa. Whole blood will be processed using the Cervos KEYPRP kit and a centrifuge. After processing, 9 mL (or less) of LAM is injected first followed immediately by 2 mL (or less) of LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo Comparator for LAM + LP-PRP)
Description: Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect about 30 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice (9 mL + 2 mL) into the osteoarthritic knee joint (Arm D, Study 2).
Study: NCT06593431

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidative Radiation
Description: Participants will receive treatment through radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidative Radiation
Description: Participants will receive treatment through radiation therapy
Study: NCT06681220

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PARP inhibitor/Temozolomide
Description: PARP inhibitor 200mg/day +Temozolomide 40mg/day daily will be given in combination x21 days each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion x 21 days each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin
Description: Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion x 21 days each cycle
Study: NCT06679881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucrictibant
Description: Deucrictibant extended-release tablet for once daily oral use
Study: NCT06679855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone infusion
Description: An intravenous (iv) infusion of milrinone will be administered at an initial dose of 0.33 mcg/kg/min and accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: An iv infusion of placebo (0.9% saline) of equivalent volume will be administered. The infusion will be accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes) to ensure blinding is maintained.